Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors

Rákkutatás · Renal cell carcinoma

This study identified that the presence of renal/adrenal metastases was significantly associated with a lower incidence of endocrine immune‑related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The study investigated predictors of endocrine immune-related adverse events (irAEs) among 72 renal cell carcinoma (RCC) patients receiving first‑line immune checkpoint inhibitors (ICIs) alone or combined with anti‑angiogenic agents between 2018 and 2023. 51.4% of patients developed at least one endocrine irAE, predominantly thyroid dysfunction (89%). Lower International Metastatic RCC Database Consortium scores and the presence of renal/adrenal metastases were linked to a reduced risk of endocrine irAEs and thyroid dysfunction. Tumour stage and sex interacted: male patients with TNM stage II–III had higher irAE rates, whereas stage IV showed a lower incidence. Tyrosine kinase inhibitor (TKI) therapy emerged as a positive predictor of thyroid dysfunction, and a lower neutrophil percentage was associated with increased endocrine irAE risk. These findings suggest that specific oncological and laboratory parameters may help identify RCC patients at higher likelihood of endocrine irAEs, informing surveillance strategies.

Better understanding of risk factors for endocrine irAEs can guide clinicians to target monitoring and management to patients most likely to develop these toxicities, potentially improving treatment adherence and safety.

Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.

Eredeti forrás

Kapcsolódó jelek